



"The fact is that I have heard oncologists and nurses comment that almost too much is known about certain cancers whereas others simply languish. Researchers are working on the lesser cancers, but they need help. I want to spearhead that help." – Paul Poth, founder, 2009

TargetCancer is making a significant impact through targeted grants supporting innovative research into rare and underfunded cancers.

\$32,000 to create *The TargetCancer Cholangiocarcinoma Cell Line Bank at Massachusetts General Hospital*

This unique initiative unites researchers, surgeons, pathologists, and clinicians towards the goal of developing and preserving cholangiocarcinoma cell line samples from patients, a critical tool for advancing research. The Cell Line Bank serves as a resource to the entire cholangiocarcinoma research community.

\$60,000 over two years to Nabeel Bardeesy's lab at the Massachusetts General Hospital Cancer Center

This grant is specifically designated for Dr. Bardeesy's groundbreaking cholangiocarcinoma research, which is yielding major discoveries in a disease that was previously receiving little attention.

\$10,000 to Dr. Adam Bass' lab at the Dana-Farber Cancer Institute to support esophageal cancer research

Dr. Bass is carrying out the largest genomic study of esophageal cancer ever attempted, and making significant discoveries about this lethal cancer that is increasing in incidence.

\$25,000 over three years to establish the TargetCancer Medical Student Research Fund at Harvard Medical School

This fellowship supports the summer studies of two students (per year) interested in studying rare cancers and innovative techniques for treating cancer.

\$7,500 to the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center

The original TargetCancer grant made by founder Paul Poth, supporting efforts to match individual cancer patients with particular targeted drug therapies.

You can read more about all of these grants at our website: www.targetcancer.info

TargetCancer promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.

TargetCancer is a registered 501 (c)(3) public charity, EIN 26-4510094

www.targetcancer.info www.righttracktunes.org

facebook.com/targetcancer twitter.com/targetcancer